Your browser doesn't support javascript.
Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.
Maeda, Kenji; Higashi-Kuwata, Nobuyo; Kinoshita, Noriko; Kutsuna, Satoshi; Tsuchiya, Kiyoto; Hattori, Shin-Ichiro; Matsuda, Kouki; Takamatsu, Yuki; Gatanaga, Hiroyuki; Oka, Shinichi; Sugiyama, Haruhito; Ohmagari, Norio; Mitsuya, Hiroaki.
  • Maeda K; Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan. kmaeda@ri.ncgm.go.jp.
  • Higashi-Kuwata N; Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan.
  • Kinoshita N; Disease Control and Prevention Center (DCC), NCGM, Tokyo, Japan.
  • Kutsuna S; Disease Control and Prevention Center (DCC), NCGM, Tokyo, Japan.
  • Tsuchiya K; AIDS Clinical Center, NCGM, Tokyo, Japan.
  • Hattori SI; Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan.
  • Matsuda K; Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan.
  • Takamatsu Y; Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan.
  • Gatanaga H; AIDS Clinical Center, NCGM, Tokyo, Japan.
  • Oka S; AIDS Clinical Center, NCGM, Tokyo, Japan.
  • Sugiyama H; Respiratory Medicine, NCGM Center Hospital, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center (DCC), NCGM, Tokyo, Japan.
  • Mitsuya H; Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan. hmitsuya@hosp.ncgm.go.jp.
Sci Rep ; 11(1): 5563, 2021 03 10.
Article in English | MEDLINE | ID: covidwho-1125955
ABSTRACT
While there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-convalescent plasmas using cell-based assays with multiple endpoints. IgG fractions from 27 cases (62.8%) had significant neutralizing activity and moderately to potently inhibited SARS-CoV-2 infection in cell-based assays; however, no detectable neutralizing activity was found in 16 cases (37.2%). Approximately half of the patients (~ 41%), who had significant neutralizing activity, lost the neutralization activity within ~ 1 month. Despite the rapid decline of neutralizing activity in plasmas, good amounts of SARS-CoV-2-S1-binding antibodies were persistently seen. The longer exposure of COVID-19 patients to greater amounts of SARS-CoV-2 elicits potent immune response to SARS-CoV-2, producing greater neutralization activity and SARS-CoV-2-S1-binding antibody amounts. The dilution of highly-neutralizing plasmas with poorly-neutralizing plasmas relatively readily reduced neutralizing activity. The presence of good amounts of SARS-CoV-2-S1-binding antibodies does not serve as a surrogate ensuring the presence of good neutralizing activity. In selecting good COVID-19-convalescent plasmas, quantification of neutralizing activity in each plasma sample before collection and use is required.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / COVID-19 Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-84733-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / COVID-19 Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-84733-5